Q-omics provides the consensus-scored METTL25 profile across patient tissues and cancer cell-line models. METTL25 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, METTL25 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, METTL25 RNA expression shows 20,277 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where METTL25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL25 survival associations across molecular data types. METTL25 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL25 RNA expression–survival associations across cancer types. High METTL25 expression shows unfavorable associations in LIHC and LGG, but favorable associations in KIRC, MESO, BRCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for METTL25 RNA expression.
This table summarizes METTL25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for METTL25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL25 shows lower tumor expression in THCA, KICH, COAD, UCEC and HNSC and higher tumor expression in LIHC. The THCA box plot shows higher METTL25 RNA expression in normal versus tumor tissue (log2 FC = −0.627, t-test p < 0.001).
This table shows molecular features associated with METTL25 in patient tissues and cancer cell lines. In patient samples, METTL25 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
